Trial of NovoSeven® in Haemophilia - Joint Bleeds

Novo Nordisk

Status and phase: Completed; Phase 4

Conditions: Haemophilia B With Inhibitors; Haemophilia A With Inhibitors; Congenital Bleeding Disorder

Treatments: Drug: Feiba VH; Drug: eptacog alfa (activated)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00108797

F7HAEM-2068

Details and patient eligibility

About

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

Enrollment: 42 patients

Sex: Male

Ages: Under 20 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)